Osgood-Schlatter disease

disease
On this page

Also known as aseptic necrosis of the tibial tubercleOsgood-Schlatter's diseaseosteochondritis of the tibial tubercleOsteochondrosis of the tibial tubercle

Summary

Osgood-Schlatter disease (MONDO:0004241) is a disease and 14 clinical trials. Top therapeutic interventions include dextrose. A subtype of bone inflammation disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide)
  • Phenotypes (HPO): 8
  • Clinical trials: 14

Clinical features

Signs & symptoms

Clinical features (HPO)

8 HPO clinical features (Orphanet curated; top 8 by frequency):

HPO IDTermFrequency
HP:0030839Knee painVery frequent (80-99%)
HP:0001288Gait disturbanceFrequent (30-79%)
HP:0003045Abnormal patella morphologyFrequent (30-79%)
HP:0003066Limited knee extensionFrequent (30-79%)
HP:0006456Irregular proximal tibial epiphysesFrequent (30-79%)
HP:0009046Difficulty runningFrequent (30-79%)
HP:0002362Shuffling gaitOccasional (5-29%)
HP:0030866Large kneeOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical nameOsgood-Schlatter disease
Mondo IDMONDO:0004241
Orphanet97335
DOIDDOID:7489
ICD-10-CMM92.52
NCITC34874
SNOMED CT430506003, 72047008
UMLSC0029376
MedGen10489
GARD0019364
MedDRA10031130
Is cancer (heuristic)no

Also known as: aseptic necrosis of the tibial tubercle · Osgood-Schlatter disease · Osgood-Schlatter’s disease · osteochondritis of the tibial tubercle · Osteochondrosis of the tibial tubercle

Disease family

This is a subtype of bone inflammation disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorderskeletal system disorderbone disorderbone inflammation diseaseOsgood-Schlatter disease

Related subtypes (5): mastoiditis, epicondylitis, osteomyelitis, arthritic joint disease, Caffey disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified13
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01300754PHASE1/PHASE2COMPLETEDEffectiveness of Dextrose Injection for Osgood-Schlatter Disease
NCT06995794Not specifiedNOT_YET_RECRUITINGOsgood-Schlatter Disease in Athletic Children
NCT07096037Not specifiedNOT_YET_RECRUITINGSafety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes
NCT07446517Not specifiedRECRUITINGLow-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes
NCT07521280Not specifiedNOT_YET_RECRUITINGIndividualized Rehabilitation for Osgood-Schlatter or Sever Pain in Youth Athletes
NCT02799394Not specifiedCOMPLETEDEffect of Activity Modification and Exercises in Young Adolescents With Osgood Schlatter Disease.
NCT02824172Not specifiedCOMPLETEDTreatment of the Osgood Schlatter
NCT03589001Not specifiedCOMPLETED24 Month Follow-up of Patients With Osgood Schlatter (OSD)
NCT04716608Not specifiedCOMPLETEDTreatment for Osgood Schlatter Patients With a Physiotherapy Program
NCT05174182Not specifiedCOMPLETEDA Comparison of Two Different Treatment Approaches for Adolescents With Osgood Schlatter
NCT05789095Not specifiedCOMPLETEDRate of Torque Development in Adolescents With Osgood-Schlatter
NCT05826340Not specifiedUNKNOWNGetting Kids With Osgood Schlatter Back to Performing Without Pain
NCT06993363Not specifiedCOMPLETEDKinesotaping and Strengthening Exercises in Treatment of Osgood-Schlatter Disease
NCT07590128Not specifiedCOMPLETEDCombined Physical Therapy and Hold-Relax Technique for Adolescent Osgood-Schlatter Knee Pain

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DEXTROSE41
CHEMBL42370701